N′-Nitrosonornicotine (NNN) and
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK), which always occur together and are present exclusively in
tobacco products, are classified as “carcinogenic to humans”
(Group 1) by the International Agency for Research on Cancer. While
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) serves
as an excellent biomarker for NNK exposure, the currently available
biomarker for NNN exposure is urinary “total NNN” (free
NNN plus its N-glucuronide). Quantitation of urinary
NNN requires extensive precautions to prevent artifactual formation
of NNN resulting from nitrosation of nornicotine during analysis.
NNN itself can also be formed endogenously by the same nitrosation
reaction, which may sometimes cause an overestimation of exposure
to preformed NNN. It is thus important to develop an alternative biomarker
to specifically reflect NNN metabolic fate and facilitate relevant
cancer etiology studies. In this study, we report the first detection
of N′-nitrosonornicotine-1N-oxide (NNN-N-oxide) in human urine. Using a highly
specific and sensitive MS3 transition-based method, NNN-N-oxide was quantified with a mean level of 8.40 ±
6.04 fmol/mL in the urine of 10 out of 32 cigarette smokers. It occurred
in a substantially higher level in the urine of 13 out of 14 smokeless
tobacco users, amounting to a mean concentration of 85.2 ± 96.3
fmol/mL urine. No NNN-N-oxide was detected in any
of the nonsmoker urine samples analyzed (n = 20).
The possible artifactual formation of NNN-N-oxide
during sample preparation steps was excluded by experiments using
added ammonium sulfamate. The low levels of NNN-N-oxide in the urine of tobacco users indicate that the pyridine N-oxidation pathway represents a minor detoxification pathway
of NNN, which further supports the importance of the α-hydroxylation
pathway of NNN metabolic activation in humans.